~~<i id='8045E75EFA'><strike id='8045E75EFA'><tt id='8045E75EFA'><pre id='8045E75EFA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

comprehensive

author：explore 2025-10-02 08:57:32 - browse：55352

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Crinetics acromegaly drug succeeds in late

focus

hotspot

Wikipedia

focus

AdobeHaveyoueverneededtoreadaresearchpaper,onlytofinditwaslockedbehindapaywall?Yournextstepwaslikely

WSS

Lawsuit highlights wrinkle for disputes over surprise medical bills

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Flu, Covid vaccination rates decline, new survey data show

Medicare innovation center doesn’t save money, experts say

Lawsuit highlights wrinkle for disputes over surprise medical bills

6 solutions to address cancer drug shortages and others

leisure time

comprehensive

focus

Trump demands the U.S. pay no more for drugs than other countries … again

European officials brace for rough respiratory virus season

Jerome Adams on the need for new antivirals for Covid

The (many) problems with a new study criticizing cancer screening

The high cost of giving birth even with insurance

Lawsuit highlights wrinkle for disputes over surprise medical bills

Activists slam private health insurers over coverage restrictions

Trump surgeon general acknowledges mistakes during Covid

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

'Make People Better': The CRISPR babies story you probably don't know

hotspot

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Medicaid rebukes states for mistakenly disenrolling children

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Amazon on where the company's health care bets are headed next

The 10 drugs up first for Medicare price negotiation

Flu, Covid vaccination rates decline, new survey data show

hotspot

Wikipedia

focus

focus